Mechanisms and clinical effects of thiazolidinediones

Expert Opinion on Investigational Drugs

Volumn 6, Issue 8, 1997, Pages 1025-1040

  Grossman, S L ^a   Lessem, J ^a  

^a Takeda Pharmaceuticals North America Inc   (United States)

Author keywords

Mechanisms; Pioglitazone; Thiazolidinediones; Troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR KINASE; LIPID; PEROXISOME PROLIFERATOR; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIVER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PEROXISOME; PHOSPHORYLATION; REVIEW; UNITED STATES;

EID: 0030825579     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.6.8.1025     Document Type: Review

References (99)